3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neuroblastoma
4
Lung Neoplasms
4
Small Cell Lung Carcinoma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Central Nervous System Neoplasms
3
Brain Neoplasms
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Burkitt Lymphoma
2
Astrocytoma
2
Spinal Cord Neoplasms
1
Rhabdoid Tumor
1
Recurrence
1
Pinealoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Nervous System Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Interventions
pembrolizumab
127
Carboplatin
109
Pemetrexed
77
Paclitaxel
76
Cisplatin
74
Nivolumab
56
Docetaxel
53
Erlotinib Hydrochloride
50
Gemcitabine
49
Radiotherapy
48
Bevacizumab
32
osimertinib
31
Cetuximab
29
atezolizumab
25
Cyclophosphamide
25
durvalumab
24
130-nm albumin-bound paclitaxel
22
Oxaliplatin
19
Fluorouracil
18
Taxes
17
Radiosurgery
17
fludarabine
16
Magnetic Resonance Spectroscopy
16
Gefitinib
16
Ipilimumab
15
Vinorelbine
14
Leucovorin
14
Albumin-Bound Paclitaxel
14
Vorinostat
13
Radiation
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Non-Small-Cell Lung
×
etoposide phosphate
×
Clear all
NCT01840579
2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1
Completed
57 enrolled
60 charts